@entity308 is diagnosed in 5-15% of @entity1 during pregnancy, increasing the risk of negative outcomes. @entity905 (FX), a selective @entity750 reuptake inhibitor, is prescribed during pregnancy. In adults, FX alters sleep patterns with single doses decreasing total sleep time and rapid eye @entity10522 . The effects of FX on sleep in the fetus are unknown. However, @entity2476 , the precursor of @entity750 , has been reported to prolong high-voltage (HV) electrocortical (ECoG) activity and increase the incidence of fetal breathing movements (FBM) in the @entity742 fetus. We hypothesize that FX exposure will decrease the incidence of LV ECoG in the fetus. Twenty-one pregnant @entity742 were surgically prepared for chronic study of blood gases, ECoG activity, eye movements and FBM. After 3 days of recovery, ewes received a 70-mg bolus i.v. infusion of FX or sterile water followed by continuous infusion at a rate of 0.036 mg/min for 8 days. The incidence of low-voltage (LV) ECoG decreased from 54+/-4% on the preinfusion day to 45+/-5% on infusion day 1 in the FX group and remained decreased throughout the infusion period. In addition, the incidence of both eye movements and FBM was decreased on infusion day 1 compared to preinfusion day in the FX group. HV ECoG increased from 39+/-3% on preinfusion day to 68+/-14% on FX infusion day 1 and remained elevated throughout the infusion period. These data show that maternal FX administration alters fetal behavioural state.

Fetal behavioural state changes following maternal @entity905 infusion in XXXX .

@entity1 :: ('9606', 'Species') :: ['women'] @entity308 :: ('MESH:D003866', 'Disease') :: ['Clinical depression'] @entity905 :: ('MESH:D005473', 'Chemical') :: ['Fluoxetine'] @entity742 :: ('9940', 'Species') :: ['sheep'] @entity10522 :: ('MESH:D020189', 'Disease') :: ['movement sleep'] @entity2476 :: ('CHEBI:28171', 'Chemical') :: ['5-hydroxytryptophan'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin']
@entity742 :: (9940,Species) :: ['sheep']
